CYP19A1 gene polymorphisms and risk of lung cancer


Zhang Jie12,Yin Yue1,Niu Xiao-Min3,Liu Yun3,Garfield David1,Chen Su-Feng1,Wang Rui1,Wang Lei1,Chen Hai-Quan1


1. Department of Thoracic Surgery, Shanghai Cancer Hospital, Fudan University, Shanghai, China

2. Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

3. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University


Objectives To investigate the association between polymorphisms of aromatase (encoded by the CYP19A1 gene and a key enzyme in biosynthesis of oestradiol) and the risk of lung cancer, and whether there were differences stratified by sex and smoking history. Methods This case–control study included consecutive, nonselected and pathologically-confirmed lung cancer patients and healthy people. Participants were classed as nonsmokers or smokers by questionnaire. Peripheral blood samples from all participants were genotyped for three single-nucleotide polymorphism (SNPs; rs727479, rs730154 and rs10046); allelic frequencies were compared across genotype and clinical records. Results A total of 529 patients with lung cancer and 567 age- and sex-matched controls were included. After adjustment for age, sex and smoking history, rs727479 was significantly associated with the incidence of lung cancer (for alleles AC vs AA). There was also a significant difference between patients and controls in haplotype CCA, while haplotype ACA was only significantly associated with nonsmokers and female nonsmokers. Conclusions Polymorphisms of CYP19A1 may be related to the increased risk of lung cancer; in particular, haplotype ACA may contribute to lung-cancer progression in nonsmokers. Further validation with larger populations is required.


SAGE Publications


Biochemistry, medical,Cell Biology,Biochemistry,General Medicine







Copyright © 2019-2021 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3